R&D at J&J Innovative Medicine. Medical oncologist. Views mine. Tweets are not medical advice
Philadelphia, PA
Joined April 2011
- Tweets3.9K
- Following1.2K
- Followers5.4K
- Likes4.5K
Joshua Bauml, MD retweeted
Grateful to @JNJInnovation for the opportunity to be the lead author on #COCOON trial #PRO data at #ASCO25. It meant a lot to be a co-investigator and true partner and help shape the secondary endpoint to measure what matters to patients (#QOL matters)!
#LCSM
Great to see @jillfeldman4 present results from #COCOON here at #ASCO25 on quality of life and prevention of skin reactions. At @JNJInnovMed we work collaboratively with all in the medical community to advance care for patients. #MyCompany
Joshua Bauml, MD retweeted
Great to see @jillfeldman4 present results from #COCOON here at #ASCO25 on quality of life and prevention of skin reactions. At @JNJInnovMed we work collaboratively with all in the medical community to advance care for patients. #MyCompany
Joshua Bauml, MD retweeted
Looking forward to sharing the story of how the @JNJInnovMed team working in partnership with the medical community @szusmani @mvmateos @cbcbc1971 has been at the forefront of innovation in developing bispecifics in oncology. Register to join. #MyCompany
jnjstorydevelopingbispecific…
Joshua Bauml, MD retweeted
Proud to share my latest podcast episode. Meet @Jbauml He has great story & doing great work for the cancer community @JNJInnovMed @MAWildgust @PolishRunner84 @BKenney1 @RebeccaGenin @RitaRibeiroMBA @carolinepavis @JackieZima #lungcancer #cancerresearch
tinyurl.com/mr3skrcf
Joshua Bauml, MD retweeted
Update on #Mariposa study for #EGFR #NSCLC from @JNJInnovation. Providing more hope for patients. #MyCompany
prnewswire.com/news-releases…
Joshua Bauml, MD retweeted
🚨Major breakthrough from #PressRelease
The MARIPOSA study reports a statistically significant and clinically meaningful improvement in overall survival (OS), reshaping the treatment landscape for patients with EGFR mutant NSCLC 🚀
jnj.com/media-center/press-r…
Joshua Bauml, MD retweeted
#NEWS: The U.S. FDA has approved our targeted therapy in combination with chemotherapy for patients with previously treated #NSCLC with specific EGFR mutations. Learn more here: jnj.com/media-center/press-r…
#JNJOncology
Joshua Bauml, MD retweeted
SQ Ami is a game changer simplifying delivery of Amivamtamab, reducing health care burden and is preferred by patients with 5 fold reduction in infusion related reactions #paloma3 #WCLC24 @muschollings @MUSChealth
For US #HCPs at #WCLC24: see Dr. Mariam Alexander (@MariamAlex26) present patient satisfaction & resource utilization results from Phase 3 PALOMA-3 study of subcutaneous EGFRxMET bispecific antibody + 3rd-gen TKI in EGFR-mutated advanced or metastatic non-small cell #LungCancer.
Joshua Bauml, MD retweeted
🎯 EMA approves amivantamab in combination with chemo for the treatment of adult patients with advanced EGFR-mutated NSCLC after Osimertinib (Mariposa2 combo) jnj.com/media-center/press-r…
Joshua Bauml, MD retweeted
Reminiscent of results from IMPRESS with gefitinib. Possible confounder here is delay to second line therapy in the continuation group. But PFS with osi + 2L chemo was 5.5m and 2L chemo alone was 7.4m. Prospective COMPEL trial will be very important.
clinicaltrials.gov/study/NCT…
Joshua Bauml, MD retweeted
Exciting news for the #EGFR #lungcancer community! The FDA has approved amivantanab + lazertinib as a first-line therapy for #EGFR #NSCLC! This new option brings promising PFS benefits from the MARIPOSA study to more patients—something we’ve needed for far too long.
Remember, more options mean more hope, but they also mean oncologists need to thoroughly discuss these choices with us. And let’s not forget the importance of addressing dermatologic side effects right from the start.
More choices = More hope!
@EGFRResisters #LCSM #OncoAlert @OncBrothers
bit.ly/3yLUaN5
Joshua Bauml, MD retweeted
#NEWS: We're pleased to announce the U.S. FDA has granted priority review of our application for a subcutaneous treatment for patients with EGFR-mutated #NSCLC. Learn more about the submission: jnj.com/media-center/press-r…
ALT Image of orange and purple lungs on blue background. The image also has text that reads: “U.S. FDA Filing Acceptance for our subcutaneous treatment for patients with EGFR-mutated non-small cell lung cancer (NSCLC)”
Joshua Bauml, MD retweeted
Our very own @Jbauml @JNJInnovMed presenting @DAVAOnc #DavaLung our #LungCancer portfolio! #MyCompany
Joshua Bauml, MD retweeted
Amivantamab, an antibody against MET and EGFR, plus lazertinib, an EGFR tyrosine kinase inhibitor, induced a response in 86% of previously untreated patients and led to a median progression-free survival of nearly 2 years. Full MARIPOSA trial results: nej.md/3zkBeFi
ALT Kaplan–Meier estimates of progression-free survival in the amivantamab–lazertinib group as compared with the osimertinib group, as assessed by blinded independent central review.
Joshua Bauml, MD retweeted
Summary of our paper scim.ag/7p1 on combining JAK inhibitors with anti-PD1 for lung cancer (NSCLC). Part of a bench-to-bedside journey to understand opposing roles of IFN in IO. Wonderful team w @EJohnWherry @divijmathew Caitlin Foley @MMarmarelis @Jbauml et al! 1/13
Joshua Bauml, MD retweeted
Exciting new paper from @divijmathew highlighting the ability to drug the "immunopharmacology" of checkpoint blockade to improve responses in NSCLC. aPD1+transient JAK inhibition. A great collaboration with @andyjminn. Similar work from J.Teijaro @scripps www-science-org.proxy.librar…
Joshua Bauml, MD retweeted
PALOMA-3 results @JCO_ASCO after #ASCO24 oral presentation. Subcutaneous vs intravenous amivantamab (with lazertinib) in previously treated #EGFR NSCLC (n=418). Primary PK endpoint shows non-inferiority. Subcutaneous with much better safety profile.
ascopubs.org/doi/10.1200/JCO…
Joshua Bauml, MD retweeted
RYBREVANT® marketing application submitted to European Medicines Agency based on PALOMA-3 study. #MyCompany
prnewswire.com/news-releases…
Joshua Bauml, MD retweeted
Dr. @EnriquetaFelip at #ASCO24 presenting data from MARIPOSA (1L amivantamab + lazertinib vs osimertinib) in pts with high risk #EGFR NSCLC. Previously reported: ami/lazer with superior PFS over lazertinib (mPFS 23.7m vs 16.6m, HR 0.70). Here - high risk subsets.
